Beechcraft M-346N Unveiled as Ready-Now Solution for U.S. Navy Undergraduate Jet Training System
28.7.2025 18:00:00 CEST | Business Wire | Press Release
Textron Aviation Defense LLC, a Textron Inc. (NYSE: TXT) company, today announced its offering of the Beechcraft M-346N jet as a “ready-now” solution from an iconic American company for the U.S. Navy Undergraduate Jet Training System (UJTS) program. The U.S. Navy has released several Requests for Information related to an upcoming Request for Proposals for a new aircraft for the UJTS program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250728874218/en/
Ready Now Beechcraft M-346N
Textron Aviation Defense and Leonardo have entered into a teaming agreement to work together to meet the Navy’s requirements for its new jet trainer. The Beechcraft M-346N is part of a proven integrated training system based on the original M-346 aircraft developed by Leonardo. More than 100 Leonardo M-346 aircraft are already meeting the demanding student pilot training needs for 4th and 5th generation air forces worldwide, including at Italy’s globally renowned International Flight Training School (IFTS).
“With our heritage deeply rooted in the strength and reliability of American manufacturing, the Beechcraft M-346N joins a proud lineup of aircraft built on 95 years of aviation excellence,” said Travis Tyler, president and CEO, Textron Aviation Defense. “The aircraft can be the cornerstone for the Navy’s future of undergraduate jet training, combining operationally-proven performance with cutting-edge technologies.”
Textron Aviation Defense, headquartered in Wichita, Kansas, manufactures Cessna and Beechcraft aircraft for military missions around the world. Since World War II, militaries have relied on these iconic brands for high-performance training and tactical aircraft.
About the Beechcraft M-346N
The Beechcraft M-346N — a twin-engine, tandem-seat aircraft with fully digital flight controls and avionics — is equipped with a fly-by-wire flight control system with quadruple redundancy, a cutting-edge human-machine interface with Head-Up Display and Large Area Display in each cockpit, hands on throttle and stick (HOTAS) controls and innovative safety features such as the Automatic Ground Collision Avoidance System (Auto-GCAS).
Fitted with two Honeywell F124-GA-200 turbofan engines, the M-346N delivers an inherently high level of safety along with impressive performance, including a maximum cruise speed of more than 590 knots and a service ceiling of 45,000 ft.
The aircraft’s advanced aerodynamic design enables exceptional maneuverability and energy management, while the elevated rear cockpit gives instructors excellent visibility in all phases of flight. The result is a trainer that effectively bridges basic instruction and the high-performance world of carrier-based fighter operations.
Advanced integrated training: A complete ecosystem
The comprehensive M-346N integrated training ecosystem, which has been validated and continuously improved through the global operational experience of the M-346 integrated training system, is poised to provide the Navy with a complete solution that enhances student readiness and operational effectiveness while reducing training costs and risks.
The Beechcraft M-346N leverages the operationally-proven Embedded Training System avionics suite for basic to advanced tactical training emulating sensors, weapons and Computer Generated Forces. This enables students to interact in real-time through a Live-Virtual-Constructive (LVC) training architecture that links aircraft in flight (Live), simulators (Virtual) and computer-generated friendly and adversary forces (Constructive). The innovative system also features adaptive training powered by Artificial Intelligence which continuously analyzes student pilot performance data to personalize learning paths, automate evaluations and tailor instruction to individual strengths and areas for improvement.
Together with its full spectrum of high-fidelity ground-based training devices — comprising simulators, computer training devices, mission planning / management tools and a carrier-based LVC environment — the Beechcraft M-346N offers a complete solution for training the next generation of Navy and Marine Corps aviators.
About Textron Aviation Defense LLC
With a legacy of thousands of proven Beechcraft and Cessna Integrated Training Systems produced and missionized in America’s Heartland since WWII, military customers turn to Textron Aviation Defense when they need airborne solutions for their critical missions. Provider of the world’s foremost military flight trainer, Textron Aviation Defense equips militaries worldwide and leads in low acquisition, sustainment and training costs. The Beechcraft T-6 Texan II fleet of more than 1,000 aircraft has logged more than 5 million hours across two NATO military flight schools and fourteen countries since 2001. Textron Aviation Defense is a subsidiary of Textron Aviation Inc.
About Textron Aviation
We inspire the journey of flight. For more than 95 years, Textron Aviation has empowered our collective talent across the Beechcraft, Cessna and Hawker brands to design and deliver the best aviation experience for our customers. With a range that includes everything from business jets, turboprops and high-performance pistons, to special missions, military trainer and defense products, Textron Aviation has the most versatile and comprehensive aviation product portfolio in the world and a workforce that has produced more than half of all general aviation aircraft worldwide. Customers in more than 170 countries rely on our legendary performance, reliability and versatility, along with our trusted global customer service network, for affordable, productive and flexible flight.
For more information, visit www.txtav.com| specialmissions.txtav.com| defense.txtav.com| scorpion.txtav.com.
About Textron Inc.
Textron Inc. is a multi-industry company that leverages its global network of aircraft, defense, industrial and finance businesses to provide customers with innovative solutions and services. Textron is known around the world for its powerful brands such as Bell, Cessna, Beechcraft, Pipistrel, Jacobsen, Kautex, Lycoming, E-Z-GO and Textron Systems.
For more information, visit: www.textron.com.
Certain statements in this press release may project revenues or describe strategies, goals, outlook or other non-historical matters; these forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update them. These statements are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the risk that the U.S. Navy does not choose the Beechcraft M-346N for the UJTS program.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250728874218/en/
Contacts
Media Contact:
Rachel Williams
+1. 316.517.5653
rawilliams@txtav.com
txtav.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.txtav.com%2
F&esheet=54297561&newsitemid=20250728874218&lan=en-US&anchor=txtav.com&index=9&m
d5=52929eaa9e18ee96b0952c4e57a55e13
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom